Identical clinical trial packages no longer secure synchronized transatlantic drug approvals.
A growing regulatory divide between the FDA and EMA splits the market access of cutting-edge therapies based on differing risk-benefit tolerances.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
It outlines how exactly identical therapeutic profile evaluations have completely diverged across transatlantic lines.
European authorities approved the drug for neuroinflammation based on HERCULES trial data while US regulators left the application stalled.
The EMA rejected the same clinical dataset for a rare transplant complication that the FDA had previously accepted for a full US approval.
The European regulatory committee rejected the application for a drug already approved and available to patients in the United States.
European regulators recommended refusing marketing authorization for a drug that the FDA had already approved as the first and only option for TA-TMA.